Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Analyzing the Composition of Tears to Identify Cancer (ACT)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Tenenbaum Family Foundation
Information provided by (Responsible Party):
University of Arkansas
ClinicalTrials.gov Identifier:
NCT00574678
First received: December 13, 2007
Last updated: January 24, 2014
Last verified: January 2014

December 13, 2007
January 24, 2014
December 2006
December 2014   (final data collection date for primary outcome measure)
This study will further evaluate the use of tumor markers (substances in body fluids that may be elevated as a consequence of certain diseases or conditions) in the diagnosis of breast and/or other cancers. [ Time Frame: Collection of specimen and analysis with SELDI-MS ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00574678 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Analyzing the Composition of Tears to Identify Cancer
ACT: Analyzing the Composition of Tears to Identify Cancer (Breast, Ovarian, Colon)

This study will further evaluate the use of protein identification or protein pattern (signature) found in tears. We hypothesize that differences exist between the protein profile in tear fluid from patients with versus without cancer.

Specifically, this study will compare the protein profile in tear fluid from patients with breast, ovarian or colon cancer versus "normal male and female patients" for differences that show promise as a diagnostic indicator. If such differences can be found, then their diagnostic potential will be assessed and developed further in a subsequent study. The long-term goal of this project will be to develop a screening tool for the detection of breast and/or other cancers.

Interventional
Phase 1
Phase 2
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
  • Breast Cancer
  • Ovarian Cancer
  • Colon Cancer
  • Benign Disease
Other: Tear collection
A tear sample (~75 microliters in a tuberculin syringe with the needle removed) will be taken at time of the initial clinic visit. After collection, the tears will be put directly on ice and taken to the lab. If it is not possible to obtain natural tears, an "eye wash" method using sterile saline will be employed and the fluid collected using the aforementioned technique. The SELDI-MS process will be conducted on the specimen immediately. The remainder of the tear specimen will be stored in a -80ºC freezer until completely analyzed.
Other Name: SELDI-MS
No Intervention: 1
Intervention: Other: Tear collection
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
150
December 2015
December 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Female or male, 18-100 years old
  • Patients who present for a routine check-up
  • Patients who present for the evaluation of an abnormal exam or test (mammogram, ultrasound, MRI, PET, etc.)
  • May or may not have a mass present
  • Patients who present for the evaluation of a palpable lump or mass
  • Patients may be pre or post biopsy for a mass, as long as there is a portion of the mass remaining

Exclusion Criteria:

  • Patient < 18 y/o or > 100 y/o
  • Concurrent eye infection or trauma
  • Active conjunctivitis
  • Abnormal production of tears (too much or too little)
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00574678
UAMS 71853
No
University of Arkansas
University of Arkansas
Tenenbaum Family Foundation
Principal Investigator: V. Suzanne Klimberg, MD University of Arkansas
University of Arkansas
January 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP